Stock dropped - during the day after earnings call.
One notable negative was that FDA announced its extending review of NKTR-181 from May 29 by 3 months to Aug 29
https://www.nasdaq.com/article/nektar-nktr-q4-earnings-beat-…
After hours – released preliminary data of NKTR-262 + NKTR-214 (bempeg) Phase 1b study:
Looks good – maybe really good – to this layperson.
https://www.nektar.com/application/files/9515/5147/6631/ASCO…